NASDAQ:TCRR

TCR2 Therapeutics Stock Forecast, Price & News

$13.04

+0.19 (+1.48 %)

(As of 08/3/2021 05:20 PM ET)

Add

Compare

Today's Range

$12.42

▼

$13.06

50-Day Range

$12.44

▼

$19.26

52-Week Range

$12.15

▼

$35.86

Volume222,922 shs

Average Volume427,175 shs

Market Capitalization$497.63 million

P/E RatioN/A

Dividend YieldN/A

Beta2.06

30 days | 90 days | 365 days | Advanced Chart

Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About TCR2 Therapeutics

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies, including adult acute lymphoblastic leukemia, DLBCL, follicular lymphoma, and other non-hodgkin lymphomas that is in phase I/II clinical trial. It is also developing TC-510 for, GPC3, IL-15, and Allogenic for solid tumors, as well as DC70 for solid tumors and hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Traders Purchase High Volume of Put Options on TCR2 Therapeutics (NASDAQ:TCRR)
July 27, 2021 | americanbankingnews.com

Were Hedge Funds Right About TCR2 Therapeutics Inc. (TCRR)?
July 26, 2021 | finance.yahoo.com

TCR2 Therapeutics (NASDAQ:TCRR) Shares Gap Up to $13.33
July 23, 2021 | americanbankingnews.com

TCR2 Therapeutics Inc. (NASDAQ:TCRR) Receives Average Rating of "Buy" from Analysts
July 22, 2021 | americanbankingnews.com

TCR2 Therapeutics (NASDAQ:TCRR) Shares Down 7.2%
July 19, 2021 | americanbankingnews.com

Analysts Anticipate TCR2 Therapeutics Inc. (NASDAQ:TCRR) Will Post Earnings of -$0.60 Per Share
July 16, 2021 | americanbankingnews.com

TCR² Therapeutics to Participate in Two Upcoming Conferences in June
May 26, 2021 | finance.yahoo.com

TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit
April 29, 2021 | finance.yahoo.com

Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
April 27, 2021 | finance.yahoo.com

TCRR May 2021 20.000 call
April 23, 2021 | ca.finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCRR
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.tcr2.com
Phone617-949-5200
Employees131
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.08 per share
Price / Book1.84

Profitability

EPS (Most Recent Fiscal Year)($2.40)
Net Income$-67,120,000.00
Net MarginsN/A
Return on Equity-30.09%
Return on Assets-28.03%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares38,162,000
Market Cap$497.63 million
Next Earnings Date8/11/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

2.27 out of 5 stars

Medical Sector

274th out of 1,309 stocks

Biological Products, Except Diagnostic Industry

38th out of 179 stocks

3.5 Analyst's Opinion

Consensus Rating
TCR2 Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $43.25, TCR2 Therapeutics has a forecasted upside of 231.7% from its current price of $13.04.
Amount of Analyst Coverage
TCR2 Therapeutics has only been the subject of 3 research reports in the past 90 days.

4.5 Community Rank

Outperform Votes
TCR2 Therapeutics has received 107 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
TCR2 Therapeutics has received 49 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
TCR2 Therapeutics has received 68.59% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about TCR2 Therapeutics and other stocks. Vote “Outperform” if you believe TCRR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TCRR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
TCR2 Therapeutics does not currently pay a dividend.
Dividend Growth
TCR2 Therapeutics does not have a long track record of dividend growth.

3.3 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TCR2 Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
27.99% of the stock of TCR2 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
98.70% of the stock of TCR2 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for TCR2 Therapeutics are expected to decrease in the coming year, from ($2.56) to ($2.93) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TCR2 Therapeutics is -5.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TCR2 Therapeutics is -5.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TCR2 Therapeutics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

TCR2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

Is TCR2 Therapeutics a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than TCR2 Therapeutics?

Wall Street analysts have given TCR2 Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TCR2 Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is TCR2 Therapeutics' next earnings date?

TCR2 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for TCR2 Therapeutics.

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) issued its earnings results on Thursday, May, 13th. The company reported ($0.58) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.03.
View TCR2 Therapeutics' earnings history.

How has TCR2 Therapeutics' stock been impacted by Coronavirus (COVID-19)?

TCR2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TCRR shares have increased by 52.0% and is now trading at $13.04.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TCRR?

9 equities research analysts have issued 12 month target prices for TCR2 Therapeutics' shares. Their forecasts range from $30.00 to $56.00. On average, they expect TCR2 Therapeutics' share price to reach $43.25 in the next twelve months. This suggests a possible upside of 231.7% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics or view top-rated stocks among Wall Street analysts.

Who are TCR2 Therapeutics' key executives?

TCR2 Therapeutics' management team includes the following people:

Dr. Garry E. Menzel M.B.A., Ph.D., Pres, CEO & Director (Age 57, Pay $941.23k)
Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 48, Pay $592.88k)
Dr. Alfonso QuintÃ¡s Cardama M.D., Chief Medical Officer (Age 50, Pay $678.58k)
Mr. Robert Hofmeister Ph.D., Chief Scientific Officer (Age 53)
Carl Mauch, Director of Investor Relations & Corp. Communications
Ms. Margaret Siegel, Head of Legal & Corp. Sec.
Dr. Angela Justice Ph.D., Chief People Officer (Age 49)
Mr. Gregg McConnell M.B.A., Head of Bus. Devel.
Mr. Stephen Turkowiak M.B.A., VP of Fin. & Treasurer

Who are some of TCR2 Therapeutics' key competitors?

Some companies that are related to TCR2 Therapeutics include C4 Therapeutics (CCCC), Rubius Therapeutics (RUBY), bluebird bio (BLUE), Cortexyme (CRTX), Century Therapeutics (IPSC), Replimune Group (REPL), Valneva (VALN), Ocugen (OCGN), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX), BioAtla (BCAB), Immunocore (IMCR), Krystal Biotech (KRYS), AlloVir (ALVR) and ImmunityBio (IBRX).
View all of TCRR's competitors.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (0.37%), New York State Common Retirement Fund (0.07%) and Alliancebernstein L.P. (0.07%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson and Robert Hofmeister.
View institutional ownership trends for TCR2 Therapeutics.

Which institutional investors are selling TCR2 Therapeutics stock?

TCRR stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. Company insiders that have sold TCR2 Therapeutics company stock in the last year include Mayur Ian Somaiya, and Robert Hofmeister.
View insider buying and selling activity for TCR2 Therapeutics or view top insider-selling stocks.

Which institutional investors are buying TCR2 Therapeutics stock?

TCRR stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., and New York State Common Retirement Fund.
View insider buying and selling activity for TCR2 Therapeutics or or view top insider-buying stocks.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $13.04.

How much money does TCR2 Therapeutics make?

TCR2 Therapeutics has a market capitalization of $497.63 million. The company earns $-67,120,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis.

How many employees does TCR2 Therapeutics have?

TCR2 Therapeutics employs 131 workers across the globe.

What is TCR2 Therapeutics' official website?

The official website for TCR2 Therapeutics is www.tcr2.com.

Where are TCR2 Therapeutics' headquarters?

TCR2 Therapeutics is headquartered at 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]

This page was last updated on 8/4/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here